25 XP   0   0   10

Zydus Lifesciences Limited
Buy, Hold or Sell?

Let's analyse Zydus Lifesciences Limited together

PenkeI guess you are interested in Zydus Lifesciences Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Zydus Lifesciences Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Zydus Lifesciences Limited

I send you an email if I find something interesting about Zydus Lifesciences Limited.

Quick analysis of Zydus Lifesciences Limited (30 sec.)










What can you expect buying and holding a share of Zydus Lifesciences Limited? (30 sec.)

How much money do you get?

How much money do you get?
INR0.13
When do you have the money?
1 year
How often do you get paid?
90.0%

What is your share worth?

Current worth
INR193.85
Expected worth in 1 year
INR224.77
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
INR41.44
Return On Investment
4.1%

For what price can you sell your share?

Current Price per Share
INR999.70
Expected price per share
INR696.50 - INR
How sure are you?
50%

1. Valuation of Zydus Lifesciences Limited (5 min.)




Live pricePrice per Share (EOD)

INR999.70

Intrinsic Value Per Share

INR70.24 - INR298.39

Total Value Per Share

INR264.09 - INR492.24

2. Growth of Zydus Lifesciences Limited (5 min.)




Is Zydus Lifesciences Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$2.3b$2.2b$76.1m3.2%

How much money is Zydus Lifesciences Limited making?

Current yearPrevious yearGrowGrow %
Making money$235.2m$538.4m-$303.2m-128.9%
Net Profit Margin11.6%30.3%--

How much money comes from the company's main activities?

3. Financial Health of Zydus Lifesciences Limited (5 min.)




What can you expect buying and holding a share of Zydus Lifesciences Limited? (5 min.)

Welcome investor! Zydus Lifesciences Limited's management wants to use your money to grow the business. In return you get a share of Zydus Lifesciences Limited.

What can you expect buying and holding a share of Zydus Lifesciences Limited?

First you should know what it really means to hold a share of Zydus Lifesciences Limited. And how you can make/lose money.

Speculation

The Price per Share of Zydus Lifesciences Limited is INR999.70. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Zydus Lifesciences Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Zydus Lifesciences Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR193.85. Based on the TTM, the Book Value Change Per Share is INR7.73 per quarter. Based on the YOY, the Book Value Change Per Share is INR40.29 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR2.63 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Zydus Lifesciences Limited.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.230.0%0.230.0%0.530.1%0.270.0%0.220.0%
Usd Book Value Change Per Share0.090.0%0.090.0%0.480.0%0.260.0%0.200.0%
Usd Dividend Per Share0.030.0%0.030.0%0.040.0%0.040.0%0.030.0%
Usd Total Gains Per Share0.120.0%0.120.0%0.530.1%0.300.0%0.230.0%
Usd Price Per Share5.90-5.90-4.18-4.55-6.96-
Price to Earnings Ratio25.47-25.47-7.95-19.41-45.64-
Price-to-Total Gains Ratio47.45-47.45-7.93-23.49-51.21-
Price to Book Ratio2.54-2.54-1.87-2.56-9.90-
Price-to-Total Gains Ratio47.45-47.45-7.93-23.49-51.21-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share11.9964
Number of shares83
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.030.04
Usd Book Value Change Per Share0.090.26
Usd Total Gains Per Share0.120.30
Gains per Quarter (83 shares)10.3224.57
Gains per Year (83 shares)41.2798.28
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1103131138588
221627227170186
3319211340255284
44212315453340382
55215419567425480
66318523680509578
77321627794594676
884246318107679774
994277359120764872
10105308400134849970

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%20.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%20.00.00.0100.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.00.01.090.0%19.00.01.095.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%20.00.00.0100.0%

Fundamentals of Zydus Lifesciences Limited

About Zydus Lifesciences Limited

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company offers the products under the Everyuth and Nutralite, Complan, Glucon D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India.

Fundamental data was last updated by Penke on 2024-03-23 20:56:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of Zydus Lifesciences Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Zydus Lifesciences Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Zydus Lifesciences Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 11.6% means that ₹0.12 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Zydus Lifesciences Limited:

  • The MRQ is 11.6%. The company is making a huge profit. +2
  • The TTM is 11.6%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ11.6%TTM11.6%0.0%
TTM11.6%YOY30.3%-18.6%
TTM11.6%5Y15.9%-4.2%
5Y15.9%10Y15.0%+0.8%
1.1.2. Return on Assets

Shows how efficient Zydus Lifesciences Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Zydus Lifesciences Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • 7.6% Return on Assets means that Zydus Lifesciences Limited generated ₹0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Zydus Lifesciences Limited:

  • The MRQ is 7.6%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 7.6%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ7.6%TTM7.6%0.0%
TTM7.6%YOY16.1%-8.5%
TTM7.6%5Y9.1%-1.5%
5Y9.1%10Y10.3%-1.2%
1.1.3. Return on Equity

Shows how efficient Zydus Lifesciences Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Zydus Lifesciences Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • 11.2% Return on Equity means Zydus Lifesciences Limited generated ₹0.11 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Zydus Lifesciences Limited:

  • The MRQ is 11.2%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 11.2%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ11.2%TTM11.2%0.0%
TTM11.2%YOY26.4%-15.2%
TTM11.2%5Y16.6%-5.4%
5Y16.6%10Y20.4%-3.7%

1.2. Operating Efficiency of Zydus Lifesciences Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Zydus Lifesciences Limited is operating .

  • Measures how much profit Zydus Lifesciences Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Zydus Lifesciences Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 19.7% means the company generated ₹0.20  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Zydus Lifesciences Limited:

  • The MRQ is 19.7%. The company is operating efficient. +1
  • The TTM is 19.7%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ19.7%TTM19.7%0.0%
TTM19.7%YOY18.2%+1.5%
TTM19.7%5Y18.0%+1.7%
5Y18.0%10Y18.2%-0.1%
1.2.2. Operating Ratio

Measures how efficient Zydus Lifesciences Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.83 means that the operating costs are ₹0.83 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Zydus Lifesciences Limited:

  • The MRQ is 0.831. The company is less efficient in keeping operating costs low.
  • The TTM is 0.831. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.831TTM0.8310.000
TTM0.831YOY0.833-0.002
TTM0.8315Y0.8310.000
5Y0.83110Y0.827+0.004

1.3. Liquidity of Zydus Lifesciences Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Zydus Lifesciences Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.81 means the company has ₹1.81 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Zydus Lifesciences Limited:

  • The MRQ is 1.811. The company is able to pay all its short-term debts. +1
  • The TTM is 1.811. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.811TTM1.8110.000
TTM1.811YOY1.564+0.247
TTM1.8115Y1.339+0.472
5Y1.33910Y1.303+0.036
1.3.2. Quick Ratio

Measures if Zydus Lifesciences Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Zydus Lifesciences Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.23 means the company can pay off ₹1.23 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Zydus Lifesciences Limited:

  • The MRQ is 1.226. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.226. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.226TTM1.2260.000
TTM1.226YOY1.452-0.227
TTM1.2265Y1.014+0.211
5Y1.01410Y0.663+0.352

1.4. Solvency of Zydus Lifesciences Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Zydus Lifesciences Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Zydus Lifesciences Limited to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.24 means that Zydus Lifesciences Limited assets are financed with 23.6% credit (debt) and the remaining percentage (100% - 23.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Zydus Lifesciences Limited:

  • The MRQ is 0.236. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.236. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.236TTM0.2360.000
TTM0.236YOY0.314-0.079
TTM0.2365Y0.387-0.151
5Y0.38710Y0.449-0.062
1.4.2. Debt to Equity Ratio

Measures if Zydus Lifesciences Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Zydus Lifesciences Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 34.6% means that company has ₹0.35 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Zydus Lifesciences Limited:

  • The MRQ is 0.346. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.346. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.346TTM0.3460.000
TTM0.346YOY0.514-0.168
TTM0.3465Y0.768-0.422
5Y0.76810Y0.926-0.158

2. Market Valuation of Zydus Lifesciences Limited

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Zydus Lifesciences Limited generates.

  • Above 15 is considered overpriced but always compare Zydus Lifesciences Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 25.47 means the investor is paying ₹25.47 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Zydus Lifesciences Limited:

  • The EOD is 51.795. Based on the earnings, the company is expensive. -2
  • The MRQ is 25.468. Based on the earnings, the company is overpriced. -1
  • The TTM is 25.468. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD51.795MRQ25.468+26.328
MRQ25.468TTM25.4680.000
TTM25.468YOY7.951+17.517
TTM25.4685Y19.409+6.059
5Y19.40910Y45.638-26.229
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Zydus Lifesciences Limited:

  • The EOD is 61.243. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 30.113. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 30.113. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD61.243MRQ30.113+31.130
MRQ30.113TTM30.1130.000
TTM30.113YOY39.576-9.463
TTM30.1135Y24.950+5.163
5Y24.95010Y45.226-20.277
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Zydus Lifesciences Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 2.54 means the investor is paying ₹2.54 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Zydus Lifesciences Limited:

  • The EOD is 5.157. Based on the equity, the company is overpriced. -1
  • The MRQ is 2.536. Based on the equity, the company is underpriced. +1
  • The TTM is 2.536. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD5.157MRQ2.536+2.621
MRQ2.536TTM2.5360.000
TTM2.536YOY1.872+0.663
TTM2.5365Y2.562-0.026
5Y2.56210Y9.903-7.341
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Zydus Lifesciences Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--7.7307.7300%40.286-81%21.313-64%16.392-53%
Book Value Per Share--193.849193.8490%186.119+4%150.855+29%104.285+86%
Current Ratio--1.8111.8110%1.564+16%1.339+35%1.303+39%
Debt To Asset Ratio--0.2360.2360%0.314-25%0.387-39%0.449-47%
Debt To Equity Ratio--0.3460.3460%0.514-33%0.768-55%0.926-63%
Dividend Per Share--2.6302.6300%3.636-28%3.356-22%2.892-9%
Eps--19.30119.3010%43.832-56%22.705-15%17.935+8%
Free Cash Flow Per Share--16.32416.3240%8.806+85%16.484-1%8.402+94%
Free Cash Flow To Equity Per Share---27.002-27.0020%0.324-8426%2.687-1105%2.026-1433%
Gross Profit Margin--0.2060.2060%0.694-70%0.311-34%0.280-26%
Intrinsic Value_10Y_max--298.388--------
Intrinsic Value_10Y_min--70.239--------
Intrinsic Value_1Y_max--19.420--------
Intrinsic Value_1Y_min--8.141--------
Intrinsic Value_3Y_max--66.337--------
Intrinsic Value_3Y_min--23.650--------
Intrinsic Value_5Y_max--122.884--------
Intrinsic Value_5Y_min--38.152--------
Market Cap1005928146995.200+50%499242694090.050499242694090.0500%356774296100.000+40%387254036342.010+29%593244942081.005-16%
Net Profit Margin--0.1160.1160%0.303-62%0.159-27%0.150-23%
Operating Margin--0.1970.1970%0.182+8%0.180+9%0.182+8%
Operating Ratio--0.8310.8310%0.8330%0.8310%0.827+0%
Pb Ratio5.157+51%2.5362.5360%1.872+35%2.562-1%9.903-74%
Pe Ratio51.795+51%25.46825.4680%7.951+220%19.409+31%45.638-44%
Price Per Share999.700+51%491.550491.5500%348.500+41%379.050+30%579.875-15%
Price To Free Cash Flow Ratio61.243+51%30.11330.1130%39.576-24%24.950+21%45.226-33%
Price To Total Gains Ratio96.495+51%47.44747.4470%7.935+498%23.487+102%51.213-7%
Quick Ratio--1.2261.2260%1.452-16%1.014+21%0.663+85%
Return On Assets--0.0760.0760%0.161-53%0.091-16%0.103-26%
Return On Equity--0.1120.1120%0.264-58%0.166-33%0.204-45%
Total Gains Per Share--10.36010.3600%43.921-76%24.669-58%19.285-46%
Usd Book Value--2362596000.0002362596000.0000%2286456000.000+3%1849471200.000+28%1279248000.000+85%
Usd Book Value Change Per Share--0.0930.0930%0.483-81%0.256-64%0.197-53%
Usd Book Value Per Share--2.3262.3260%2.233+4%1.810+29%1.251+86%
Usd Dividend Per Share--0.0320.0320%0.044-28%0.040-22%0.035-9%
Usd Eps--0.2320.2320%0.526-56%0.272-15%0.215+8%
Usd Free Cash Flow--198948000.000198948000.0000%108180000.000+84%202190400.000-2%103056000.000+93%
Usd Free Cash Flow Per Share--0.1960.1960%0.106+85%0.198-1%0.101+94%
Usd Free Cash Flow To Equity Per Share---0.324-0.3240%0.004-8426%0.032-1105%0.024-1433%
Usd Market Cap12071137763.942+50%5990912329.0815990912329.0810%4281291553.200+40%4647048436.104+29%7118939304.972-16%
Usd Price Per Share11.996+51%5.8995.8990%4.182+41%4.549+30%6.959-15%
Usd Profit--235236000.000235236000.0000%538476000.000-56%278558400.000-16%220137600.000+7%
Usd Revenue--2025336000.0002025336000.0000%1779312000.000+14%1754097600.000+15%1437949200.000+41%
Usd Total Gains Per Share--0.1240.1240%0.527-76%0.296-58%0.231-46%
 EOD+4 -4MRQTTM+0 -0YOY+17 -195Y+15 -2110Y+19 -17

3.2. Fundamental Score

Let's check the fundamental score of Zydus Lifesciences Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1551.795
Price to Book Ratio (EOD)Between0-15.157
Net Profit Margin (MRQ)Greater than00.116
Operating Margin (MRQ)Greater than00.197
Quick Ratio (MRQ)Greater than11.226
Current Ratio (MRQ)Greater than11.811
Debt to Asset Ratio (MRQ)Less than10.236
Debt to Equity Ratio (MRQ)Less than10.346
Return on Equity (MRQ)Greater than0.150.112
Return on Assets (MRQ)Greater than0.050.076
Total7/10 (70.0%)

3.3. Technical Score

Let's check the technical score of Zydus Lifesciences Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5065.326
Ma 20Greater thanMa 50972.673
Ma 50Greater thanMa 100870.183
Ma 100Greater thanMa 200762.625
OpenGreater thanClose1,027.750
Total5/5 (100.0%)



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets257,564,000
Total Liabilities60,681,000
Total Stockholder Equity175,158,000
 As reported
Total Liabilities 60,681,000
Total Stockholder Equity+ 175,158,000
Total Assets = 257,564,000

Assets

Total Assets257,564,000
Total Current Assets100,164,000
Long-term Assets157,400,000
Total Current Assets
Cash And Cash Equivalents 4,878,000
Short-term Investments 9,326,000
Net Receivables 44,254,000
Inventory 34,133,000
Other Current Assets 7,573,000
Total Current Assets  (as reported)100,164,000
Total Current Assets  (calculated)100,164,000
+/-0
Long-term Assets
Property Plant Equipment 68,267,000
Goodwill 48,044,000
Intangible Assets 10,905,000
Long-term Assets Other 8,287,000
Long-term Assets  (as reported)157,400,000
Long-term Assets  (calculated)135,503,000
+/- 21,897,000

Liabilities & Shareholders' Equity

Total Current Liabilities55,307,000
Long-term Liabilities5,374,000
Total Stockholder Equity175,158,000
Total Current Liabilities
Short-term Debt 11,751,000
Short Long Term Debt 11,632,000
Accounts payable 21,250,000
Other Current Liabilities 2,705,000
Total Current Liabilities  (as reported)55,307,000
Total Current Liabilities  (calculated)47,338,000
+/- 7,969,000
Long-term Liabilities
Capital Lease Obligations 317,000
Long-term Liabilities  (as reported)5,374,000
Long-term Liabilities  (calculated)317,000
+/- 5,057,000
Total Stockholder Equity
Common Stock1,012,000
Retained Earnings 171,898,000
Accumulated Other Comprehensive Income 248,000
Other Stockholders Equity 2,000,000
Total Stockholder Equity (as reported)175,158,000
Total Stockholder Equity (calculated)175,158,000
+/-0
Other
Capital Stock1,012,000
Cash and Short Term Investments 14,204,000
Common Stock Shares Outstanding 1,015,650
Current Deferred Revenue19,601,000
Liabilities and Stockholders Equity 257,564,000
Net Debt 7,071,000
Net Invested Capital 186,790,000
Net Working Capital 44,857,000
Property Plant and Equipment Gross 68,267,000
Short Long Term Debt Total 11,949,000



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-312013-03-312012-03-312011-03-312010-03-312009-03-312008-03-312007-03-312006-03-312005-03-312004-03-31
> Total Assets 
13,423,000
13,602,000
15,730,000
20,112,000
25,699,000
33,835,000
37,384,000
45,672,000
63,792,000
73,722,000
79,865,000
90,471,000
100,163,000
152,207,000
180,653,000
234,831,000
236,866,000
238,847,000
277,954,000
257,564,000
257,564,000277,954,000238,847,000236,866,000234,831,000180,653,000152,207,000100,163,00090,471,00079,865,00073,722,00063,792,00045,672,00037,384,00033,835,00025,699,00020,112,00015,730,00013,602,00013,423,000
   > Total Current Assets 
5,022,000
5,070,000
6,491,000
9,871,000
11,223,000
16,049,000
17,749,000
22,829,000
27,631,000
31,917,000
34,537,000
42,267,000
44,376,000
60,223,000
82,297,000
84,981,000
87,154,000
87,160,000
122,614,000
100,164,000
100,164,000122,614,00087,160,00087,154,00084,981,00082,297,00060,223,00044,376,00042,267,00034,537,00031,917,00027,631,00022,829,00017,749,00016,049,00011,223,0009,871,0006,491,0005,070,0005,022,000
       Cash And Cash Equivalents 
442,000
612,000
438,000
990,000
926,000
2,517,000
2,507,000
2,952,000
4,666,000
5,838,000
5,488,000
6,699,000
6,953,000
15,435,000
13,149,000
4,207,000
8,453,000
6,652,000
6,578,000
4,878,000
4,878,0006,578,0006,652,0008,453,0004,207,00013,149,00015,435,0006,953,0006,699,0005,488,0005,838,0004,666,0002,952,0002,507,0002,517,000926,000990,000438,000612,000442,000
       Short-term Investments 
0
0
0
0
0
0
0
0
30,000
933,000
644,000
1,212,000
2,331,000
614,000
4,772,000
5,797,000
4,943,000
4,620,000
28,470,000
9,326,000
9,326,00028,470,0004,620,0004,943,0005,797,0004,772,000614,0002,331,0001,212,000644,000933,00030,00000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
47,563,000
45,779,000
43,498,000
50,324,000
44,254,000
44,254,00050,324,00043,498,00045,779,00047,563,000000000000000000
       Inventory 
1,700,000
2,108,000
2,338,000
3,717,000
4,593,000
5,853,000
7,504,000
8,119,000
10,905,000
12,136,000
13,675,000
15,357,000
14,512,000
18,037,000
23,853,000
26,880,000
27,890,000
32,362,000
37,194,000
34,133,000
34,133,00037,194,00032,362,00027,890,00026,880,00023,853,00018,037,00014,512,00015,357,00013,675,00012,136,00010,905,0008,119,0007,504,0005,853,0004,593,0003,717,0002,338,0002,108,0001,700,000
       Other Current Assets 
2,880,000
2,350,000
3,715,000
5,164,000
5,704,000
7,679,000
7,738,000
11,758,000
12,030,000
13,010,000
14,730,000
18,999,000
20,580,000
26,137,000
40,523,000
534,000
89,000
28,000
48,000
7,573,000
7,573,00048,00028,00089,000534,00040,523,00026,137,00020,580,00018,999,00014,730,00013,010,00012,030,00011,758,0007,738,0007,679,0005,704,0005,164,0003,715,0002,350,0002,880,000
   > Long-term Assets 
8,401,000
8,532,000
9,239,000
10,241,000
14,476,000
17,786,000
19,635,000
22,843,000
36,161,000
41,805,000
45,328,000
48,204,000
55,787,000
91,984,000
98,356,000
149,850,000
149,712,000
151,687,000
155,340,000
157,400,000
157,400,000155,340,000151,687,000149,712,000149,850,00098,356,00091,984,00055,787,00048,204,00045,328,00041,805,00036,161,00022,843,00019,635,00017,786,00014,476,00010,241,0009,239,0008,532,0008,401,000
       Property Plant Equipment 
5,050,000
5,585,000
6,231,000
7,581,000
9,357,000
10,605,000
12,598,000
15,472,000
22,018,000
27,558,000
30,491,000
32,154,000
36,490,000
50,026,000
54,511,000
59,431,000
61,937,000
63,332,000
64,226,000
68,267,000
68,267,00064,226,00063,332,00061,937,00059,431,00054,511,00050,026,00036,490,00032,154,00030,491,00027,558,00022,018,00015,472,00012,598,00010,605,0009,357,0007,581,0006,231,0005,585,0005,050,000
       Goodwill 
0
0
0
0
0
0
4,796,000
0
0
9,232,000
8,989,000
8,950,000
8,937,000
11,494,000
13,853,000
52,890,000
53,915,000
53,465,000
53,646,000
48,044,000
48,044,00053,646,00053,465,00053,915,00052,890,00013,853,00011,494,0008,937,0008,950,0008,989,0009,232,000004,796,000000000
       Intangible Assets 
2,191,000
1,944,000
1,721,000
1,861,000
4,315,000
6,041,000
933,000
0
11,300,000
822,000
673,000
397,000
2,469,000
13,153,000
12,816,000
17,688,000
13,868,000
12,363,000
11,272,000
10,905,000
10,905,00011,272,00012,363,00013,868,00017,688,00012,816,00013,153,0002,469,000397,000673,000822,00011,300,0000933,0006,041,0004,315,0001,861,0001,721,0001,944,0002,191,000
       Long-term Assets Other 
981,000
844,000
1,091,000
602,000
583,000
790,000
1,308,000
1,717,000
2,661,000
4,914,000
5,597,000
7,583,000
9,890,000
3,477,000
-1,360,000
1,689,000
96,000
5,471,000
5,890,000
8,287,000
8,287,0005,890,0005,471,00096,0001,689,000-1,360,0003,477,0009,890,0007,583,0005,597,0004,914,0002,661,0001,717,0001,308,000790,000583,000602,0001,091,000844,000981,000
> Total Liabilities 
8,059,000
7,668,000
8,734,000
11,315,000
14,883,000
21,255,000
20,707,000
23,288,000
37,152,000
43,084,000
44,032,000
46,266,000
45,290,000
81,046,000
91,298,000
118,039,000
119,762,000
89,551,000
87,416,000
60,681,000
60,681,00087,416,00089,551,000119,762,000118,039,00091,298,00081,046,00045,290,00046,266,00044,032,00043,084,00037,152,00023,288,00020,707,00021,255,00014,883,00011,315,0008,734,0007,668,0008,059,000
   > Total Current Liabilities 
2,532,000
2,666,000
3,009,000
5,446,000
5,051,000
6,915,000
8,661,000
11,188,000
21,562,000
26,704,000
28,140,000
32,649,000
34,071,000
53,058,000
59,828,000
73,425,000
82,694,000
78,613,000
78,394,000
55,307,000
55,307,00078,394,00078,613,00082,694,00073,425,00059,828,00053,058,00034,071,00032,649,00028,140,00026,704,00021,562,00011,188,0008,661,0006,915,0005,051,0005,446,0003,009,0002,666,0002,532,000
       Short-term Debt 
0
0
0
0
0
0
0
55,000
6,871,000
14,918,000
13,382,000
15,009,000
15,456,000
27,388,000
28,516,000
39,497,000
47,847,000
39,830,000
38,427,000
11,751,000
11,751,00038,427,00039,830,00047,847,00039,497,00028,516,00027,388,00015,456,00015,009,00013,382,00014,918,0006,871,00055,0000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
47,718,000
39,740,000
38,339,000
11,632,000
11,632,00038,339,00039,740,00047,718,0000000000000000000
       Accounts payable 
1,549,000
1,630,000
1,973,000
3,844,000
3,641,000
5,255,000
6,146,000
8,306,000
5,455,000
6,568,000
9,108,000
10,909,000
13,449,000
16,736,000
18,884,000
19,226,000
20,310,000
22,059,000
21,378,000
21,250,000
21,250,00021,378,00022,059,00020,310,00019,226,00018,884,00016,736,00013,449,00010,909,0009,108,0006,568,0005,455,0008,306,0006,146,0005,255,0003,641,0003,844,0001,973,0001,630,0001,549,000
       Other Current Liabilities 
983,000
1,036,000
1,036,000
1,602,000
1,410,000
1,660,000
2,515,000
2,827,000
9,236,000
5,218,000
5,650,000
6,731,000
5,166,000
8,818,000
11,908,000
14,165,000
164,000
241,000
345,000
2,705,000
2,705,000345,000241,000164,00014,165,00011,908,0008,818,0005,166,0006,731,0005,650,0005,218,0009,236,0002,827,0002,515,0001,660,0001,410,0001,602,0001,036,0001,036,000983,000
   > Long-term Liabilities 
5,527,000
5,002,000
5,725,000
5,869,000
9,832,000
14,340,000
12,046,000
12,100,000
15,590,000
16,380,000
15,892,000
13,617,000
11,219,000
27,988,000
31,470,000
44,614,000
37,068,000
10,938,000
9,022,000
5,374,000
5,374,0009,022,00010,938,00037,068,00044,614,00031,470,00027,988,00011,219,00013,617,00015,892,00016,380,00015,590,00012,100,00012,046,00014,340,0009,832,0005,869,0005,725,0005,002,0005,527,000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,777,000
4,692,000
5,240,000
0
05,240,0004,692,0004,777,0000000000000000000
> Total Stockholder Equity
5,364,000
5,934,000
6,989,000
8,655,000
10,622,000
12,352,000
16,285,000
21,715,000
25,736,000
29,445,000
34,390,000
42,516,000
53,519,000
69,600,000
87,445,000
103,863,000
103,757,000
129,923,000
169,996,000
175,158,000
175,158,000169,996,000129,923,000103,757,000103,863,00087,445,00069,600,00053,519,00042,516,00034,390,00029,445,00025,736,00021,715,00016,285,00012,352,00010,622,0008,655,0006,989,0005,934,0005,364,000
   Common Stock
314,000
314,000
314,000
628,000
628,000
682,000
682,000
1,024,000
1,024,000
1,024,000
1,024,000
1,024,000
1,024,000
1,024,000
1,024,000
1,024,000
1,024,000
1,024,000
1,024,000
1,012,000
1,012,0001,024,0001,024,0001,024,0001,024,0001,024,0001,024,0001,024,0001,024,0001,024,0001,024,0001,024,0001,024,000682,000682,000628,000628,000314,000314,000314,000
   Retained Earnings 
720,000
933,000
1,593,000
223,000
1,092,000
1,704,000
0
0
0
11,263,000
15,283,000
23,381,000
34,660,000
50,463,000
67,707,000
82,643,000
86,124,000
113,842,000
154,958,000
171,898,000
171,898,000154,958,000113,842,00086,124,00082,643,00067,707,00050,463,00034,660,00023,381,00015,283,00011,263,0000001,704,0001,092,000223,0001,593,000933,000720,000
   Capital Surplus 00000000000000000000
   Treasury Stock00000000000000000000
   Other Stockholders Equity 
4,330,000
4,687,000
5,082,000
7,804,000
8,902,000
9,966,000
15,603,000
20,691,000
24,712,000
17,158,000
18,083,000
18,111,000
17,835,000
18,113,000
18,714,000
20,196,000
2,000,000
2,000,000
2,000,000
2,000,000
2,000,0002,000,0002,000,0002,000,00020,196,00018,714,00018,113,00017,835,00018,111,00018,083,00017,158,00024,712,00020,691,00015,603,0009,966,0008,902,0007,804,0005,082,0004,687,0004,330,000



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue168,778,000
Cost of Revenue-63,101,000
Gross Profit105,677,000105,677,000
 
Operating Income (+$)
Gross Profit105,677,000
Operating Expense-77,149,000
Operating Income28,528,00028,528,000
 
Operating Expense (+$)
Research Development1,358,000
Selling General Administrative5,829,000
Selling And Marketing Expenses15,572,000
Operating Expense77,149,00022,759,000
 
Net Interest Income (+$)
Interest Income757,000
Interest Expense-1,299,000
Other Finance Cost-757,000
Net Interest Income-1,299,000
 
Pretax Income (+$)
Operating Income28,528,000
Net Interest Income-1,299,000
Other Non-Operating Income Expenses0
Income Before Tax (EBT)25,897,00030,213,000
EBIT - interestExpense = 31,939,000
25,481,000
20,902,000
Interest Expense1,299,000
Earnings Before Interest and Taxes (EBIT)33,238,00027,196,000
Earnings Before Interest and Taxes (EBITDA)40,465,000
 
After tax Income (+$)
Income Before Tax25,897,000
Tax Provision-5,878,000
Net Income From Continuing Ops20,965,00020,019,000
Net Income19,603,000
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses140,250,000
Total Other Income/Expenses Net-1,685,0001,299,000
 

Technical Analysis of Zydus Lifesciences Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Zydus Lifesciences Limited. The general trend of Zydus Lifesciences Limited is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Zydus Lifesciences Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Zydus Lifesciences Limited.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: .

The bearish price targets are: 1,016 > 921.70 > 696.50.

Tweet this
Zydus Lifesciences Limited Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Zydus Lifesciences Limited. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Zydus Lifesciences Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Zydus Lifesciences Limited. The current macd is 35.91.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Zydus Lifesciences Limited price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Zydus Lifesciences Limited. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Zydus Lifesciences Limited price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Zydus Lifesciences Limited Daily Moving Average Convergence/Divergence (MACD) ChartZydus Lifesciences Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Zydus Lifesciences Limited. The current adx is 48.70.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Zydus Lifesciences Limited shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Zydus Lifesciences Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Zydus Lifesciences Limited. The current sar is 947.88.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Zydus Lifesciences Limited Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Zydus Lifesciences Limited. The current rsi is 65.33. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Zydus Lifesciences Limited Daily Relative Strength Index (RSI) ChartZydus Lifesciences Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Zydus Lifesciences Limited. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Zydus Lifesciences Limited price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Zydus Lifesciences Limited Daily Stochastic Oscillator ChartZydus Lifesciences Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Zydus Lifesciences Limited. The current cci is 113.37.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Zydus Lifesciences Limited Daily Commodity Channel Index (CCI) ChartZydus Lifesciences Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Zydus Lifesciences Limited. The current cmo is 23.39.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Zydus Lifesciences Limited Daily Chande Momentum Oscillator (CMO) ChartZydus Lifesciences Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Zydus Lifesciences Limited. The current willr is -30.06955591.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Zydus Lifesciences Limited is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Zydus Lifesciences Limited Daily Williams %R ChartZydus Lifesciences Limited Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Zydus Lifesciences Limited.

Zydus Lifesciences Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Zydus Lifesciences Limited. The current atr is 28.18.

Zydus Lifesciences Limited Daily Average True Range (ATR) ChartZydus Lifesciences Limited Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Zydus Lifesciences Limited. The current obv is 154,373,844.

Zydus Lifesciences Limited Daily On-Balance Volume (OBV) ChartZydus Lifesciences Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Zydus Lifesciences Limited. The current mfi is 57.89.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Zydus Lifesciences Limited Daily Money Flow Index (MFI) ChartZydus Lifesciences Limited Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Zydus Lifesciences Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-10STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-02MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Zydus Lifesciences Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Zydus Lifesciences Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5065.326
Ma 20Greater thanMa 50972.673
Ma 50Greater thanMa 100870.183
Ma 100Greater thanMa 200762.625
OpenGreater thanClose1,027.750
Total5/5 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Zydus Lifesciences Limited with someone you think should read this too:
  • Are you bullish or bearish on Zydus Lifesciences Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Zydus Lifesciences Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Zydus Lifesciences Limited

I send you an email if I find something interesting about Zydus Lifesciences Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Zydus Lifesciences Limited.

Receive notifications about Zydus Lifesciences Limited in your mailbox!